Menu Search
Equities

Ascentage Pharma Group International

6855:HKG

Ascentage Pharma Group International

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)42.95
  • Today's Change-1.25 / -2.83%
  • Shares traded132.70k
  • 1 Year change+68.10%
  • Beta1.2517
Data delayed at least 15 minutes, as of Nov 13 2024 01:45 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Ascentage Pharma Group International had net income fall 4.84% from a loss of 882.92m to a larger loss of 925.64m despite a 5.85% increase in revenues from 209.71m to 221.98m. An increase in the selling, general and administrative costs as a percentage of sales from 156.41% to 169.59% was a component in the falling net income despite rising revenues.
Gross margin96.96%
Net profit margin-39.93%
Operating margin-32.40%
Return on assets-11.97%
Return on equity-53.13%
Return on investment-16.78%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Ascentage Pharma Group International fell by 307.59m. Cash Flow from Financing totalled 368.75m or 166.12% of revenues. In addition the company used 726.08m for operations while cash from investing totalled 21.92m.
Cash flow per share-1.02
Price/Cash flow per share--
Book value per share2.64
Tangible book value per share2.28
More ▼

Balance sheet in CNYView more

Ascentage Pharma Group International has a Debt to Total Capital ratio of 68.65%, a lower figure than the previous year's 215.44%.
Current ratio1.84
Quick ratio1.83
Total debt/total equity2.22
Total debt/total capital0.6865
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.